Dr. Powell is currently the Senior Vice President and World Wide head of Pharmaceutical Development at Bristol-Myers Squibb. He is responsible for the planning and directing of all pharmaceutical development activities for all BMS compounds (small molecules and biologics) in Global Pharmaceutical Development, as well as supporting globally manufactured products as necessary. Pharmaceutical Development laboratories are located on 7 research campuses in the United States, Canada, UK and Belgium. In addition to his functional responsibilities, Mark was the Head of Diabetes Exploratory Development at BMS from 2000-2005. In that capacity he was responsible for the pharmaceutical, preclinical, and clinical exploratory development and progression of all diabetes compounds transitioning out of discovery and into Phase III clinical development.

Dr. Powell obtained his Ph.D. from the University of Washington in 1980 and has worked in the pharmaceutical industry for 27 years. His professional experiences have encompassed all aspects of preclinical, clinical and pharmaceutical development, from discovery lead compound optimization and selection through to final regulatory submission and successful product launches of both new compounds and life cycle management projects, as he has assumed increasing responsibilities throughout his career.

Dr. Powell has authored and co-authored more than 125 scientific articles and presentations which have been made at the local, national and international level, as well as given numerous invited talks. He has participated in, and moderated, many scientific discussion panels at both national and international meetings and has chaired an international scientific conference.